Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Can you spot the clinical presentation of hepatorenal syndrome-acute kidney injury (HRS-AKI)? Are you able to navigate the necessary patient evaluations for safe and effective treatment?

In this interactive Clinical Case Challenge, you'll test your ability to promptly recognize the signs of HRS-AKI and perform essential patient assessments to guide appropriate initiation of vasoconstrictor therapy in a case-based simulation. Receive immediate feedback on your decisions and see how well you can apply current HRS-AKI guidelines to a realistic patient scenario.

Afterwards, you'll have an opportunity to download a summary of key evidence and an HRS-AKI Quick Reference Guide for Nurses to strengthen recognition and response at the bedside.

• Recognize the causes, risk factors, and precipitating factors of hepatorenal syndrome-acute kidney injury (HRS-AKI)
• Identify clinical indictors and laboratory findings associated with the diagnostic criteria for HRS-AKI to support early diagnosis and intervention
• Integrate best practices for pre-treatment assessment and post-treatment monitoring of patients receiving vasoconstrictor therapy for HRS-AKI
• Apply proactive communication strategies with the multidisciplinary care team to facilitate prompt and evidence-based management of patients with HRS-AKI

Nurse Practitioner Accreditation Statement

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.25 contact hour (which includes 0.1 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Todd Frederick, MD (Speaker)
  
  Advisory Board or Panel – Ipsen, Madrigal, Mallinckrodt
  Consultant – Mallinckrodt, Miromatrix
  Grants / Research Support – AstraZeneca, Mallinckrodt, River 2 Renal, Salix
  Speakers Bureau or other Promotional Education – Madrigal
  Stock / Shareholder (self- managed) – Madrigal
  The relationships reported above are related to the following therapeutic area: Gastroenterology
• Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
  
  Speakers Bureau or other Promotional Education – Astellas, AstraZeneca, Bristol-Myers Squibb, CTI, Coherus, DSI, Dova, Eli Lilly and Company, Gilead Sciences, Morphosys, Pfizer
  The relationships reported above are related to the following therapeutic area: Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Amanda Chaney, DNP, APRN, FAANP, AF-AASLD (Speaker)
• Annette Sophin, MSMM, PA-C (Reviewer)
• Abimbola Farinde, PhD, PharmD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.